用呼吸道合胞病毒G糖蛋白单克隆抗体或F(ab')2片段进行治疗可减轻小鼠肺部炎症。
Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice.
作者信息
Miao Congrong, Radu Gertrud U, Caidi Hayat, Tripp Ralph A, Anderson Larry J, Haynes Lia M
机构信息
National Centers for Immunization and Respiratory Disease, Division of Viral Diseases, Respiratory and Gastroenteritis Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road NE, Atlanta, GA 30333, USA.
College of Veterinary Medicine, Department of Infectious Disease, University of Georgia, Athens, GA 30602, USA.
出版信息
J Gen Virol. 2009 May;90(Pt 5):1119-1123. doi: 10.1099/vir.0.009308-0. Epub 2009 Mar 4.
Abstract
Therapeutic treatment with a non-neutralizing monoclonal antibody (mAb) (131-2G) specific to respiratory syncytial virus (RSV) G glycoprotein mediates virus clearance and decreases leukocyte trafficking and interferon gamma (IFN-gamma) production in the lungs of RSV-infected mice. Its F(ab')(2) component only mediates decreased leukocyte trafficking and IFN-gamma production without reducing virus replication. Thus, this mAb has two independent actions that could facilitate treatment and/or prevention of RSV infection by reducing both virus replication and virus-induced pulmonary inflammation.
摘要
用针对呼吸道合胞病毒（RSV）G糖蛋白的非中和单克隆抗体（mAb）（131-2G）进行治疗，可介导病毒清除，并减少RSV感染小鼠肺部的白细胞迁移和γ干扰素（IFN-γ）产生。其F(ab')(2) 成分仅介导白细胞迁移减少和IFN-γ产生减少，而不降低病毒复制。因此，这种单克隆抗体有两种独立作用，可通过减少病毒复制和病毒诱导的肺部炎症来促进RSV感染的治疗和/或预防。
相似文献
1
Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice.
J Gen Virol. 2009 May;90(Pt 5):1119-1123. doi: 10.1099/vir.0.009308-0. Epub 2009 Mar 4.
2
A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice.
J Virol. 2013 Oct;87(20):10955-67. doi: 10.1128/JVI.01164-13. Epub 2013 Jul 24.
3
Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.
J Virol. 2010 Sep;84(18):9632-6. doi: 10.1128/JVI.00451-10. Epub 2010 Jun 30.
4
Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice.
J Infect Dis. 2009 Aug 1;200(3):439-47. doi: 10.1086/600108.
5
Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.
J Virol. 2014 Sep;88(18):10569-83. doi: 10.1128/JVI.01503-14. Epub 2014 Jul 2.
6
Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice.
PLoS One. 2012;7(12):e51485. doi: 10.1371/journal.pone.0051485. Epub 2012 Dec 27.
7
Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles.
J Virol. 2019 Apr 17;93(9). doi: 10.1128/JVI.00087-19. Print 2019 May 1.
8
Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection.
Am J Respir Cell Mol Biol. 2014 Jul;51(1):143-54. doi: 10.1165/rcmb.2013-0360OC.
9
Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice.
Antiviral Res. 2014 Apr;104:110-7. doi: 10.1016/j.antiviral.2014.01.022. Epub 2014 Feb 6.
10
Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults.
Front Immunol. 2019 Mar 29;10:706. doi: 10.3389/fimmu.2019.00706. eCollection 2019.
引用本文的文献
1
Quantification of RSV Antibodies in Human Plasma by Enzyme Immunoassays.
Methods Mol Biol. 2025;2948:365-374. doi: 10.1007/978-1-0716-4666-3_23.
2
Secretory Expression and Purification of Respiratory Syncytial Virus G and F Ectodomain in Human Cells.
Methods Mol Biol. 2025;2948:127-135. doi: 10.1007/978-1-0716-4666-3_9.
3
Advances in development of antiviral strategies against respiratory syncytial virus.
Acta Pharm Sin B. 2025 Apr;15(4):1752-1772. doi: 10.1016/j.apsb.2025.02.015. Epub 2025 Feb 20.
4
Protective Non-neutralizing anti-N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA.2.86-JN.1 with Superfluous In Vivo Protection against JN.1 Due to Attenuated Virulence.
J Immunol. 2024 Sep 1;213(5):678-689. doi: 10.4049/jimmunol.2300675.
5
Evolutionary trends of respiratory syncytial viruses: Insights from large-scale surveillance and molecular dynamics of G glycoprotein.
Heliyon. 2024 May 9;10(10):e30886. doi: 10.1016/j.heliyon.2024.e30886. eCollection 2024 May 30.
6
Monoclonal antibodies targeting sites in respiratory syncytial virus attachment G protein provide protection against RSV-A and RSV-B in mice.
Nat Commun. 2024 Apr 4;15(1):2900. doi: 10.1038/s41467-024-47146-2.
7
Microbiological and epidemiological features of respiratory syncytial virus.
Rev Esp Quimioter. 2024 Jun;37(3):209-220. doi: 10.37201/req/006.2024. Epub 2024 Mar 21.
8
Fc-mediated functions and the treatment of severe respiratory viral infections with passive immunotherapy - a balancing act.
Front Immunol. 2023 Nov 22;14:1307398. doi: 10.3389/fimmu.2023.1307398. eCollection 2023.
9
Anti-G protein antibodies targeting the RSV G protein CX3C chemokine region improve the interferon response.
Ther Adv Infect Dis. 2023 Mar 14;10:20499361231161157. doi: 10.1177/20499361231161157. eCollection 2023 Jan-Dec.
10
Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge.
Vaccines (Basel). 2022 Dec 5;10(12):2078. doi: 10.3390/vaccines10122078.
本文引用的文献
1
Molecular diversity of the aminoterminal region of the G protein gene of human respiratory syncytial virus subgroup B.
Pathol Biol (Paris). 2008 Mar;56(2):50-7. doi: 10.1016/j.patbio.2007.06.001. Epub 2007 Oct 4.
2
Protection of mice against Human respiratory syncytial virus by wild-type and aglycosyl mouse-human chimaeric IgG antibodies to subgroup-conserved epitopes on the G glycoprotein.
J Gen Virol. 2006 May;87(Pt 5):1267-1273. doi: 10.1099/vir.0.81660-0.
3
Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses.
J Immunol. 2006 Feb 1;176(3):1600-8. doi: 10.4049/jimmunol.176.3.1600.
4
Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis.
J Infect Dis. 2004 Dec 1;190(11):1936-40. doi: 10.1086/425516. Epub 2004 Oct 28.
5
Pathogenesis of respiratory syncytial virus infection.
Viral Immunol. 2004;17(2):165-81. doi: 10.1089/0882824041310513.
6
Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model.
Antimicrob Agents Chemother. 2004 May;48(5):1811-22. doi: 10.1128/AAC.48.5.1811-1822.2004.
7
Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.
J Virol. 2003 Sep;77(18):9831-44. doi: 10.1128/jvi.77.18.9831-9844.2003.
8
CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice.
Vaccine. 2003 Jun 20;21(21-22):2964-79. doi: 10.1016/s0264-410x(03)00119-1.
9
Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection.
J Virol. 2002 Jul;76(14):6873-81. doi: 10.1128/jvi.76.14.6873-6881.2002.
10
RSV-induced immunopathology: dynamic interplay between the virus and host immune response.
Virology. 2002 Apr 10;295(2):203-7. doi: 10.1006/viro.2002.1382.
Zotero 插件